Woodline Partners’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Woodline Partners’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-189	Closed	-$133K	–	695
2023 Q3	$133K	Buy	189 +40	+27%	+$172K	﹤0.01%	567
2023 Q2	$686K	Buy	+149	New	+$517K	0.01%	516
2022 Q4	–	Sell	-182	Closed	-$720K	–	871
2022 Q3	$720K	Sell	182 -120	-40%	-$472K	0.01%	560
2022 Q2	$788K	Sell	302 -428	-59%	-$1.11M	0.01%	537
2022 Q1	$2.35M	Sell	730 -324	-31%	-$1.39M	0.04%	362
2021 Q4	$6.6M	Sell	1,054 -86	-8%	-$660K	0.09%	252
2021 Q3	$10.6M	Buy	1,140 +347	+44%	+$2.98M	0.17%	155
2021 Q2	$8.04M	Buy	793 +608	+329%	+$9.99M	0.15%	161
2021 Q1	$3.55M	Buy	+185	New	+$2.16M	0.08%	225

Other funds holding SEEL

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Woodline Partners's SEEL Position: Q4 2023 in Review

Woodline Partners sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 189 shares — an estimated $133K sold.

Woodline Partners first reported a position in SEEL in Q1 2021 and held it in 9 quarters. The position peaked at $10.6M in Q3 2021. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

Woodline Partners reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Woodline Partners sold 189 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $133K.
Woodline Partners first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Woodline Partners's Seelos Therapeutics, Inc. Common Stock position peaked at $10.6M in Q3 2021.
32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Woodline Partners's 13F filing for Q4 2023, filed 14 Feb 2024.